December 12, 2018
Enzyvant today announced the appointment of George O. Elston as Chief Financial Officer and Head of Corporate Development, further building the capabilities of the company.
July 28, 2018
Enzyvant announced today the appointments of Andrew Dawson to head human resources and Alex Tracy, PhD to lead development and manufacturing, enhancing the overall capabilities of the company
July 19, 2018
Enzyvant today announced that it has formed a collaboration with PerkinElmer Genomics, a global genomic testing company, to screen for mutations in the ASAH1 gene.
July 9, 2018
Enzyvant, announced today that it has initiated its rolling submission of a Biologics License Application (BLA) for RVT-802 to the U.S. Food and Drug Administration (FDA).
July 5, 2018
Enzyvant today announced that it has formed a partnership with Visikol, a contract research organization focused on digital pathology and drug discovery.
June 4, 2018
Enzyvant today announced the appointments of Alan Kimura, MD, PhD as Chief Medical Officer and Tamara Joseph, JD, LLM as General Counsel.
February 28, 2018
Re:GenerationHope raises awareness and funds for the complete DiGeorge Anomaly community
October 16, 2017
Global study aims to define the natural course of Farber disease
September 5-8, 2017
Enzyvant will present two posters and an oral presentation at the WORLD Symposium in San Diego
April 17, 2017
Enzyvant receives FDA Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for RVT-802
February 15, 2017
Enzyvant will be presenting two posters at the ICIEM conference in Rio de Janeiro, Brazil
January 9-11, 2017
Come meet us at “Rare in the Square” in Union Square, San Francisco